PHC (PARIS HEPATOLOGY CONFERENCE) 2021 – PROGRAM-WEDNESDAY

Program of the day

WEDNESDAY March 10th

  • 12:30 - 13:00 EIGER BIOPHARMACEUTICALS SYMPOSIUM
  • The present state of hepatitis Delta: epidemiology, diagnosis, and current treatments - Tarik ASSELAH (France)
  • Can current research change the face of hepatitis Delta ? - Ohad ETZION (Israel)
  • Audience Q&A
  • How to make NAFLD a global public health priority ? - Jeffrey LAZARUS (Spain)
  • 14:10 - 14:30 Pathology of NAFLD/NASH revisited

    Chairman:

    Valérie PARADIS (France)
  • 14:30 - 14:40 BREAK & VISIT OF THE BOOTHS
  • DISCUSSION
  • 15:50 - 16:10 STATE OF THE ART LECTURE
  • 16:10 - 16:20 BREAK & VISIT OF THE BOOTHS
  • DISCUSSION
  • 17:20 - 17:40 STATE OF THE ART LECTURE
  • Optimal management of cholangiocarcinoma - Ulrich BEUERS (Netherlands)
  • 17:40 - 17:50 BREAK & VISIT OF THE BOOTHS
  • Gilead’s Commitment to Liver disease - Tram TRAN (USA)
  • Madrigal: Advancing Resmetirom in Phase 3 Trials for Non-cirrhotic NASH with Liver Fibrosis Rebecca TAUB, President of Research & Development - Rebecca TAUB (USA)
  • Assembly Biosciences: Developing Innovative Therapeutics Targeting Chronic HBV Infection - Luisa STAMM (USA)
  • Eiger BioPharmaceuticals: Developing Two Foundational Treatments for HDV - Jeffrey GLENN (USA)
  • Janssen